After surgery for carcinoma in situ of breast, the treatments include endocrine therapy, radiotherapy, targeted drug therapy and so on, depending on the molecular typing and surgical resection method of the patient.
Breast carcinoma in situ belongs to the very early stage of breast cancer, if the postoperative pathology suggests that the patient’s estrogen receptor is positive, or progesterone receptor is positive, or both of them are positive, and the molecular typing is hormone receptor-positive breast cancer, then the patient needs to choose the treatment of endocrine drugs such as tamoxifen, letrozole, anastrozole, and so on.
If the patient is on a breast-conserving surgical resection, whole-breast radiotherapy plus in situ supplementation needs to be given postoperatively.
If the molecular typing of the patient is HER-2 positive breast cancer, that is, the patient has high expression of HER-2 gene mutation, then the patient needs to be given trastuzumab, patuximab and other targeted drug therapy after surgery.
So it is said that breast cancer patients, under the guidance of the doctor to carry out standardized treatment, drugs should be applied under the guidance of the doctor.